ASPIC

Hotel Eurostars Oasis Plaza, Figueira da Foz, Portugal

1-3 October, 2025

See more informations here: https://www.factorchave.com/21-congresso-nacional-cancro-digestivo/

Hospital CUF Tejo, Lisboa, Portugal

23 May, 2025

See more informations here: https://academiacuf.up.events/activities/view/12184#local

Hospital CUF Tejo, Lisboa, Portugal

23 May, 2025

See more informations here: https://academiacuf.up.events/activities/view/12184#local

Autores e Afiliações:

Raquel V Mendes ¹, Joana M Ribeiro ^{# 2}, Helena Gouveia ^{# 3}, Cátia Rebelo de Almeida ¹, Mireia Castillo-Martin ^{1 4}, Maria José Brito ⁴, Rita Canas-Marques ⁴, Eva Batista ³, Celeste Alves ³, Berta Sousa ³, Pedro Gouveia ³, Miguel Godinho Ferreira ⁵, Maria João Cardoso ^{3 6}, Fatima Cardoso ³, Rita Fior ⁷

Authors and Affiliations:

Raquel V Mendes ¹, Joana M Ribeiro ^{# 2}, Helena Gouveia ^{# 3}, Cátia Rebelo de Almeida ¹, Mireia Castillo-Martin ^{1 4}, Maria José Brito ⁴, Rita Canas-Marques ⁴, Eva Batista ³, Celeste Alves ³, Berta Sousa ³, Pedro Gouveia ³, Miguel Godinho Ferreira ⁵, Maria João Cardoso ^{3 6}, Fatima Cardoso ³, Rita Fior ⁷

Work recently published in the “European Journal of Pharmacology" by Dr. Mélanie Barbosa, Dr. Ryan D. Kruschel et al., has demonstrated the potential of two isoquinolinequinone N-oxides (RK2 and RK3) as promising candidates for the next stages of drug development against multidrug resistant cancers, specifically linked to the overexpression of ABCB1. This work is the result of a collaboration of Prof. Helena Vasconcelos from i3S, University of Porto - Portugal, with Prof. Florence McCarthy, from the School of Chemistry, University College Cork - Ireland.

Trabalho recentemente publicado na revista “European Journal of Pharmacology" pela Doutora Mélanie Barbosa, Doutor Ryan D. Kruschel et al., demonstrou o potencial de dois N-óxidos de isoquinolinaquinona (RK2 e RK3) como promissores candidatos para as próximas fases de desenvolvimento de fármacos contra cancros resistentes a múltiplos fármacos, especificamente relacionados com a sobreexpressão de ABCB1. Este trabalho é o resultado de uma colaboração da Prof. Helena Vasconcelos do i3S, Universidade do Porto – Portugal, com o Prof.

In recent years, the research group at UCIBIO - Laboratory of Toxicology, Faculty of Pharmacy, University of Porto - has focused on studying metabolic reprogramming in urological cancers to identify potential biomarkers with different clinical applications, including diagnosis, prognosis, and response to treatment. The most recent study aimed to characterise the metabolic signature of renal cell carcinoma (RCC) by analysing the metabolome of renal tumour and adjacent non-tumour tissues, as well as urine samples collected from the same patients.